Medtronic NeuromodulationOctober 17, 2019

FDA 483 - Medtronic Neuromodulation - October 17, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Medtronic Neuromodulation

Record Details

An FDA inspection of Medtronic Neuromodulation in Minneapolis revealed two significant issues. The firm failed to adequately document design input requirements for interchanging programmer applications, which led to patients experiencing excessive stimulation and pain. Additionally, procedures for corrective and preventive actions related to suppliers were not properly established, with multiple CAPAs lacking essential quality records for various phases.

Company: Medtronic Neuromodulation
Inspection Date: October 17, 2019
Product Type: Device
Office: Minneapolis District Office
People: Joseph D. Gong (issuing_officer)
Susan M. Matthias (investigator)

Open in Dashboard

ID · 00137af1-6573-4e37-a715-8bd0482e134a